NCT06004128|Unknown
Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other Treatments
1 other identifier
VYD222-EA-001
Study Type
expanded_access
Target
N/A
Locations
0 countries
Sites
N/A
Timeline
RegisteredAug 2023
Brief Summary
Provide pre-approval single-patient Expanded Access (Compassionate Use) of VYD222 for patients with symptomatic COVID-19 refractory to other treatments.
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 18, 2023
Completed4 days until next milestone
First Posted
Study publicly available on registry
August 22, 2023
CompletedLast Updated
June 3, 2024
Status Verified
May 1, 2024
First QC Date
August 18, 2023
Last Update Submit
May 30, 2024
Conditions
Interventions
VYD222DRUG
Monoclonal antibody
Sponsors & Collaborators
- Invivyd, Inc.lead
MeSH Terms
Conditions
COVID-19
Condition Hierarchy (Ancestors)
Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 18, 2023
First Posted
August 22, 2023
Last Updated
June 3, 2024
Record last verified: 2024-05